vs
Side-by-side financial comparison of NATURES SUNSHINE PRODUCTS INC (NATR) and STONERIDGE INC (SRI). Click either name above to swap in a different company.
STONERIDGE INC is the larger business by last-quarter revenue ($205.2M vs $123.8M, roughly 1.7× NATURES SUNSHINE PRODUCTS INC). On growth, NATURES SUNSHINE PRODUCTS INC posted the faster year-over-year revenue change (4.7% vs -6.0%). NATURES SUNSHINE PRODUCTS INC produced more free cash flow last quarter ($7.6M vs $2.6M). Over the past eight quarters, NATURES SUNSHINE PRODUCTS INC's revenue compounded faster (5.6% CAGR vs -7.4%).
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
Stoneridge Inc is a global designer and manufacturer of advanced electrical and electronic components, integrated systems, and sensor solutions. It serves automotive, commercial vehicle, off-highway, and aerospace sectors, delivering products that boost vehicle safety, efficiency, connectivity, and environmental performance across key global markets.
NATR vs SRI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $123.8M | $205.2M |
| Net Profit | $4.1M | — |
| Gross Margin | 72.5% | 16.2% |
| Operating Margin | 4.3% | -14.4% |
| Net Margin | 3.3% | — |
| Revenue YoY | 4.7% | -6.0% |
| Net Profit YoY | 1379.4% | — |
| EPS (diluted) | $0.23 | $-2.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $123.8M | $205.2M | ||
| Q3 25 | $128.3M | $210.3M | ||
| Q2 25 | $114.8M | $228.0M | ||
| Q1 25 | $113.2M | $217.9M | ||
| Q4 24 | $118.2M | $218.2M | ||
| Q3 24 | $114.6M | $213.8M | ||
| Q2 24 | $110.6M | $237.1M | ||
| Q1 24 | $111.0M | $239.2M |
| Q4 25 | $4.1M | — | ||
| Q3 25 | $5.3M | $-9.4M | ||
| Q2 25 | $5.3M | $-9.4M | ||
| Q1 25 | $4.7M | $-7.2M | ||
| Q4 24 | $-321.0K | — | ||
| Q3 24 | $4.3M | $-7.1M | ||
| Q2 24 | $1.3M | $2.8M | ||
| Q1 24 | $2.3M | $-6.1M |
| Q4 25 | 72.5% | 16.2% | ||
| Q3 25 | 73.3% | 20.3% | ||
| Q2 25 | 71.7% | 21.5% | ||
| Q1 25 | 72.1% | 21.2% | ||
| Q4 24 | 72.0% | 19.5% | ||
| Q3 24 | 71.3% | 20.8% | ||
| Q2 24 | 71.4% | 22.7% | ||
| Q1 24 | 71.2% | 20.2% |
| Q4 25 | 4.3% | -14.4% | ||
| Q3 25 | 7.0% | -1.6% | ||
| Q2 25 | 3.7% | -1.1% | ||
| Q1 25 | 5.4% | -1.5% | ||
| Q4 24 | 3.8% | -2.0% | ||
| Q3 24 | 4.6% | 0.1% | ||
| Q2 24 | 5.1% | 1.4% | ||
| Q1 24 | 4.2% | 0.1% |
| Q4 25 | 3.3% | — | ||
| Q3 25 | 4.2% | -4.5% | ||
| Q2 25 | 4.6% | -4.1% | ||
| Q1 25 | 4.2% | -3.3% | ||
| Q4 24 | -0.3% | — | ||
| Q3 24 | 3.8% | -3.3% | ||
| Q2 24 | 1.2% | 1.2% | ||
| Q1 24 | 2.1% | -2.6% |
| Q4 25 | $0.23 | $-2.76 | ||
| Q3 25 | $0.30 | $-0.34 | ||
| Q2 25 | $0.28 | $-0.34 | ||
| Q1 25 | $0.25 | $-0.26 | ||
| Q4 24 | $-0.02 | $-0.22 | ||
| Q3 24 | $0.23 | $-0.26 | ||
| Q2 24 | $0.07 | $0.10 | ||
| Q1 24 | $0.12 | $-0.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $93.9M | $66.3M |
| Total DebtLower is stronger | — | $180.9M |
| Stockholders' EquityBook value | $161.6M | $179.8M |
| Total Assets | $261.1M | $551.2M |
| Debt / EquityLower = less leverage | — | 1.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.9M | $66.3M | ||
| Q3 25 | $95.6M | $54.0M | ||
| Q2 25 | $81.3M | $49.8M | ||
| Q1 25 | $86.5M | $79.1M | ||
| Q4 24 | $84.7M | $71.8M | ||
| Q3 24 | $78.7M | $54.1M | ||
| Q2 24 | $68.7M | $42.1M | ||
| Q1 24 | $77.8M | $48.4M |
| Q4 25 | — | $180.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $201.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $2.1M | — |
| Q4 25 | $161.6M | $179.8M | ||
| Q3 25 | $166.7M | $251.2M | ||
| Q2 25 | $163.7M | $260.5M | ||
| Q1 25 | $167.1M | $253.1M | ||
| Q4 24 | $161.0M | $245.3M | ||
| Q3 24 | $162.6M | $271.4M | ||
| Q2 24 | $156.4M | $270.5M | ||
| Q1 24 | $159.7M | $277.3M |
| Q4 25 | $261.1M | $551.2M | ||
| Q3 25 | $264.8M | $632.1M | ||
| Q2 25 | $254.9M | $639.4M | ||
| Q1 25 | $252.7M | $657.4M | ||
| Q4 24 | $240.9M | $621.6M | ||
| Q3 24 | $245.3M | $662.5M | ||
| Q2 24 | $235.8M | $666.7M | ||
| Q1 24 | $247.3M | $675.4M |
| Q4 25 | — | 1.01× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.82× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.01× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.9M | $8.8M |
| Free Cash FlowOCF − Capex | $7.6M | $2.6M |
| FCF MarginFCF / Revenue | 6.1% | 1.3% |
| Capex IntensityCapex / Revenue | 1.9% | 3.0% |
| Cash ConversionOCF / Net Profit | 2.41× | — |
| TTM Free Cash FlowTrailing 4 quarters | $28.8M | $12.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.9M | $8.8M | ||
| Q3 25 | $18.5M | $3.6M | ||
| Q2 25 | $4.3M | $10.7M | ||
| Q1 25 | $2.6M | $10.9M | ||
| Q4 24 | $12.2M | $19.2M | ||
| Q3 24 | $9.6M | $10.8M | ||
| Q2 24 | $1.3M | $8.7M | ||
| Q1 24 | $2.2M | $9.1M |
| Q4 25 | $7.6M | $2.6M | ||
| Q3 25 | $16.8M | $-2.7M | ||
| Q2 25 | $3.0M | $7.4M | ||
| Q1 25 | $1.5M | $4.8M | ||
| Q4 24 | $10.0M | $14.0M | ||
| Q3 24 | $7.9M | $4.6M | ||
| Q2 24 | $-2.0M | $1.5M | ||
| Q1 24 | $-1.5M | $3.3M |
| Q4 25 | 6.1% | 1.3% | ||
| Q3 25 | 13.1% | -1.3% | ||
| Q2 25 | 2.6% | 3.3% | ||
| Q1 25 | 1.3% | 2.2% | ||
| Q4 24 | 8.5% | 6.4% | ||
| Q3 24 | 6.9% | 2.2% | ||
| Q2 24 | -1.9% | 0.6% | ||
| Q1 24 | -1.4% | 1.4% |
| Q4 25 | 1.9% | 3.0% | ||
| Q3 25 | 1.3% | 3.0% | ||
| Q2 25 | 1.2% | 1.4% | ||
| Q1 25 | 1.0% | 2.8% | ||
| Q4 24 | 1.9% | 2.4% | ||
| Q3 24 | 1.5% | 2.9% | ||
| Q2 24 | 3.0% | 3.0% | ||
| Q1 24 | 3.3% | 2.4% |
| Q4 25 | 2.41× | — | ||
| Q3 25 | 3.46× | — | ||
| Q2 25 | 0.81× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.21× | — | ||
| Q2 24 | 0.97× | 3.11× | ||
| Q1 24 | 0.94× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
SRI
| Control Devices | $51.7M | 25% |
| Electronics | $38.0M | 19% |
| EE | $34.2M | 17% |
| SE | $28.6M | 14% |
| NL | $24.5M | 12% |
| Stoneridge Brazil | $14.1M | 7% |
| Asia Pacific | $13.1M | 6% |
